GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mithra Pharmaceuticals SA (CHIX:MITRAb) » Definitions » EV-to-Revenue

Mithra Pharmaceuticals (CHIX:MITRAB) EV-to-Revenue : 3.17 (As of Apr. 30, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Mithra Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Mithra Pharmaceuticals's enterprise value is €198.50 Mil. Mithra Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €62.68 Mil. Therefore, Mithra Pharmaceuticals's EV-to-Revenue for today is 3.17.

The historical rank and industry rank for Mithra Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

CHIX:MITRAb' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.14   Med: 13.71   Max: 126.12
Current: 3.17

During the past 11 years, the highest EV-to-Revenue of Mithra Pharmaceuticals was 126.12. The lowest was 3.14. And the median was 13.71.

CHIX:MITRAb's EV-to-Revenue is ranked worse than
62.63% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.32 vs CHIX:MITRAb: 3.17

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-30), Mithra Pharmaceuticals's stock price is €2.955. Mithra Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €1.17. Therefore, Mithra Pharmaceuticals's PS Ratio for today is 2.52.


Mithra Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Mithra Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mithra Pharmaceuticals EV-to-Revenue Chart

Mithra Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.33 10.94 98.56 47.11 5.85

Mithra Pharmaceuticals Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 47.11 - 5.85 -

Competitive Comparison of Mithra Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Mithra Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mithra Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mithra Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mithra Pharmaceuticals's EV-to-Revenue falls into.



Mithra Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Mithra Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=198.500/62.675
=3.17

Mithra Pharmaceuticals's current Enterprise Value is €198.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mithra Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €62.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mithra Pharmaceuticals  (CHIX:MITRAb) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Mithra Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.955/1.171
=2.52

Mithra Pharmaceuticals's share price for today is €2.955.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was €1.17.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mithra Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mithra Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Mithra Pharmaceuticals (CHIX:MITRAB) Business Description

Traded in Other Exchanges
Address
Rue Saint-Georges 5, Liege, BEL, 4000
Mithra Pharmaceuticals SA develops products for women's health with a particular focus on fertility, contraception, and menopause. It operates in three segments: Product Sales, Out-licensing, and Other. The company also develops and markets complex therapeutic solutions and offers partners a complete spectrum of research, development, and specialist manufacturing at its Mithra CDMO. Its geographical segments are Belgium, Europe and Outside Europe.

Mithra Pharmaceuticals (CHIX:MITRAB) Headlines

No Headlines